Appropriate Use of Pharmacotherapeutic Agents by the Orofacial Pain Dentist

1. Heir GM, Bassiur J, Branch M, et al. Core curriculum in orofacial pain postgraduate orofacial pain programs in United States–based dental school and university-based programs. J Orofac Pain 2010; 24:423–449.

2. Commission on Dental Accreditation and American Dental Association. Accreditation Standards for Advanced Education General Dentistry Education Programs in Orofacial Pain [note: referenced material from the Commission on Dental Accreditation is accurate as of July 2010]. www.ada.org/100.aspx. Accessed 8 Sept 2011.

3. Sharav Y, Benoliel R. Drugs for acute orofacial pain. In: Sharav Y, Benoliel R (eds). Orofacial Pain and Headache. Philadelphia: Mosby-Elsevier, 2008:349–377.

4. Benoliel R, Sharav Y. Drugs for chronic orofacial pain. In: Sharav Y, Benoliel R (eds). Orofacial Pain and Headache. Philadelphia: Mosby-Elsevier, 2008:378–409.

5. Raffa RB. Netter’s Illustrated Pharmacology. Teterboro, NJ: Icon Learning Systems, 2005.

6. Barile FA. Clinical Toxicology: Principles and Mechanisms. Boca Raton: CRC, 2004.

7. Saenz RE. Hardcore Pharmacology. Philadelphia: Lippincott Williams & Wilkins, 2006.

8. Dionne RA. Pharmacologic approaches. In: Laskin DM, Greene CS, Hylander WL (eds). Temporomandibular Disorders: An Evidenced-Based Approach to Diagnosis and Treatment. Chicago: Quintessence, 2006:347–357.

9. Craig CR, Stitzel RE. Modern Medical Pharmacology. New York: Little, Brown and Company, 1994.

10. Olson J. Clinical Pharmacology Made Ridiculously Simple. Miami, FL: Medmaster, 1994.

11. Janick PG, Davis JM, Preskorn SH, Ayd FJ. Principles and Practice of Psychopharmacology, ed 2. Baltimore: Williams and Wilkins, 1997.

12. Reisner-Keller LA. Pharmacotherapeutics in the management of orofacial pain. Dent Clin North Am 1997;41:259–278.

13. Haas DA. Adverse drug interactions in dental practice: Interactions associated with analgesics. Part III in a series. J Am Dent Assoc 1999;130:397–407.

14. Jeske AH. Selecting new drugs for pain control: Evidence-based decisions or clinical impressions? J Am Dent Assoc 2002;133: 1052–1056.

15. Okeson JP. Bell’s Orofacial Pains: The Clinical Management of Orofacial Pain, ed 6. Chicago: Quintessence, 2005.

16. Wright EF. Manual of Temporomandibular Disorders, ed 2. Ames, IA: Wiley-Blackwell, 2010.

17. Tollison CD. Handbook of Chronic Pain Management. Baltimore: Williams and Wilkins, 1989.

18. Swift JQ, Roszkowski MT. The use of opioid drugs in management of chronic orofacial pain. J Oral Maxillofac Surg 1998;56:1081 –1085.

19. Zuniga JR. The use of nonopioid drugs in management of chronic orofacial pain. J Oral Maxillofac Surg 1998;56:1075–1080.

20. Lobbezoo F, van Denderen RJA, Verheij JGC, Naeije M. Reports of SSRI-associated bruxism in the family physician’s office. J Orofac Pain 2001;15:340–346.

21. Winocur E, Gavish A, Voikovitch M, Emodi-Perlman A, Eli I. Drugs and bruxism: A critical review. J Orofac Pain 2003;17:99–111.

22. Brazeau GA, Gremillion HA, Widmer CG, et al. The role of pharmacy in the management of patients with temporomandibular disorders and orofacial pain. J Am Pharm Assoc 1998;38:354–361.

23. Pettengill CA, Reisner Keller L. The use of tricyclic antidepressants for the control of chronic orofacial pain. Cranio 1997;15:53–56.

24. Brown ES, Hong SC. Antidepressant-induced bruxism successfully treated with gabapentin. J Am Dent Assoc 1999;130:

1467–1469.

25. Rizzatti-Barbosa CM, Nogueira MTP, de Andrade ED, Ambrosano GMB, de Albergaria Barbosa JR. Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders. Cranio 2003;21:221–225.

26. Ikawa M, Yamada K, Ikeuchi S. Efficacy of amitriptyline for treatment of somatoform pain disorder in the orofacial region: A case series. J Orofac Pain 2006;20:234–240.

27. List T, Axelsson S, Leijon G. Pharmacologic interventions in the treatment of temporomandibular disorders, atypical facial pain, and burning mouth syndrome. A qualitative systematic review.

J Orofac Pain 2003;17:301–310.

28. Guay DRP. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001;21:1070–1081.

29. Fields H, Liebeskind J (eds). Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research and Management, vol. 1. Seattle, WA: International Society For The Study of Pain, 1994.

30. O’Connor AB, Dworkin RH. Treatment of neuropathic pain: An over-view of recent guidelines. Am J Med 2009;122(10, suppl):S22–32.

31. Epstein JB, Grushka M, Le N. Topical clonidine for orofacial pain: A pilot study. J Orofac Pain 1997;11:346–352.

32. Hansen HC. Treatment of chronic pain with antiepileptic drugs: A new era. S Med J 1999;92:642–648.

33. Horwitz M, Horwitz M, Ochs M, Carrau R, Kassam A. Trigeminal neuralgia and glossopharyngeal neuralgia. J Am Dent Assoc 2004;135:1427–1433.

34. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol 2001;429:1–11.

35. Padilla M, Clark GT, Merrill RL. Topical medications for orofacial neuropathic pain: A review. J Am Dent Assoc 2000;131:184–195.

36. Reisner L, Pettengill CA. The use of anticonvulsants in orofacial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91:2–7.

37. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389–400.

38. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002;18:22–27.

39. Spencer CJ, Gremillion HA. Neuropathic orofacial pain: Proposed mechanisms, diagnosis, and treatment considerations. Dent Clin North Am 2007;51:209–224.

40. Lee YS, Kho HS, Kim YK, Chung SC. Influence of topical capsaicin on facial sensitivity in response to experimental pain. J Oral Rehabil 2007;34:9–14.

41. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6: 346–356.

42. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuro-pathic pain. Neuropharmacology 2005;48:252–263.

43. Nasri-Heir C, Gomes J, Heir GM, et al. The role of sensory input of the chorda tympani nerve and the number of fungiform papillae in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:65–72.

44. Heir GM, Karolchek S, Kalladka M, et al. Use of topical medication in orofacial neuropathic pain: A retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:466–469.

45. Silberstein SD, Stiles A, Young WB, Rozen TD. An Atlas of Headache. New York: Parthenon, 2002.

46. Kelley WN, Harris ED, Ruddy S, Sledge CB. Textbook of Rheumatology. Philadelphia: WB Saunders, 1985.

47. Delissio D, Silberstein SD. Wolff’s Headache and Other Head Pain, ed 6. Oxford: Oxford University, 1993.

48. Spierings EL. Mechanism of migraine and action of antimigraine medications. Med Clin North Am 2001;85:943–958.

49. Goadsby PJ. Pathophysiology of migraine. Neurol Clin 2009;

27:335–360.

50. Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. BMC Med 2009;7:71.

51. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304–1312.

52. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache 2008;48:1337–1342.

53. Charles A, Flippen C, Romero Reyes M, Brennan KC. Memantine for prevention of migraine: A retrospective study of 60 cases. J Headache Pain 2007;8:248–250.

54. Drug Enforcement Administration, Office of Diversion Control. DEA Practitioner’s Manual and 21CFR1306.04. US Department of Justice, Drug Enforcement Administration, 2006. http://www. deadiversion.usdoj.gov/pubs/manuals/pract/index.html. Accessed 20 Sept 2011.